March 25, 2020 / 7:05 AM / 13 days ago

BRIEF-Exelixis Says Co's Partner Takeda Received Approval in Japan for CABOMETY (cabozantinib) Tablets

March 25 (Reuters) - Exelixis Inc:

* EXELIXIS ANNOUNCES PARTNER TAKEDA RECEIVES APPROVAL IN JAPAN FOR CABOMETYX® (CABOZANTINIB) TABLETS FOR THE TREATMENT OF CURATIVELY UNRESECTABLE OR METASTATIC RENAL CELL CARCINOMA

* EXELIXIS- CO IS ELIGIBLE TO RECEIVE $31 MILLION MILESTONE PAYMENT FROM TAKEDA UPON FIRST COMMERCIAL SALE OF CABOMETY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below